CN106701668A - 间质干细胞、其纯株化扩张的方法、其分离方法及其应用 - Google Patents
间质干细胞、其纯株化扩张的方法、其分离方法及其应用 Download PDFInfo
- Publication number
- CN106701668A CN106701668A CN201510436042.4A CN201510436042A CN106701668A CN 106701668 A CN106701668 A CN 106701668A CN 201510436042 A CN201510436042 A CN 201510436042A CN 106701668 A CN106701668 A CN 106701668A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- interstital stem
- igf1r
- cell
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 23
- 238000000926 separation method Methods 0.000 title claims abstract description 7
- 210000000130 stem cell Anatomy 0.000 claims description 400
- 210000004027 cell Anatomy 0.000 claims description 119
- 208000006011 Stroke Diseases 0.000 claims description 58
- 206010061216 Infarction Diseases 0.000 claims description 34
- 230000007574 infarction Effects 0.000 claims description 34
- 210000003954 umbilical cord Anatomy 0.000 claims description 29
- 210000005013 brain tissue Anatomy 0.000 claims description 28
- 230000004751 neurological system process Effects 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 22
- 230000006735 deficit Effects 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 208000031225 myocardial ischemia Diseases 0.000 claims description 16
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 13
- 201000006474 Brain Ischemia Diseases 0.000 claims description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 11
- 206010008118 cerebral infarction Diseases 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 210000004700 fetal blood Anatomy 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000004153 glucose metabolism Effects 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 210000003074 dental pulp Anatomy 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 abstract description 31
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract description 26
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract description 26
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 239
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 234
- 241000700159 Rattus Species 0.000 description 177
- 238000012360 testing method Methods 0.000 description 60
- 210000001519 tissue Anatomy 0.000 description 56
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 45
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 45
- 206010000891 acute myocardial infarction Diseases 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 32
- 108010081589 Becaplermin Proteins 0.000 description 28
- 238000002659 cell therapy Methods 0.000 description 25
- 230000002490 cerebral effect Effects 0.000 description 25
- 239000002609 medium Substances 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 20
- 230000000302 ischemic effect Effects 0.000 description 20
- 210000002216 heart Anatomy 0.000 description 19
- 230000000903 blocking effect Effects 0.000 description 18
- 210000005003 heart tissue Anatomy 0.000 description 17
- 230000003727 cerebral blood flow Effects 0.000 description 16
- 238000002513 implantation Methods 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 230000008676 import Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000008929 regeneration Effects 0.000 description 12
- 238000011069 regeneration method Methods 0.000 description 12
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 11
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 11
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 11
- 239000000370 acceptor Substances 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 102100022723 Interleukin-22 receptor subunit alpha-1 Human genes 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 10
- 238000010166 immunofluorescence Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 210000003194 forelimb Anatomy 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 235000015110 jellies Nutrition 0.000 description 8
- 239000008274 jelly Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 101001044883 Homo sapiens Interleukin-22 receptor subunit alpha-1 Proteins 0.000 description 7
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 7
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 7
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 6
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000002241 neurite Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 5
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 5
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 4
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000005034 decoration Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 238000002660 stem cell treatment Methods 0.000 description 4
- 208000013623 stereotypic movement disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102100022987 Angiogenin Human genes 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- -1 SSEA-4 or Nanog Proteins 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000219095 Vitis Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000006160 differential media Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 108010027445 interleukin-22 receptor Proteins 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000003188 neurobehavioral effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000013139 quantization Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000019040 Nuclear Antigens Human genes 0.000 description 2
- 108010051791 Nuclear Antigens Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- ATMYEINZLWEOQU-MOOMFTQBSA-N (3R,4S,5S,6R)-2-(18F)fluoranyl-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1OC([18F])[C@H](O)[C@@H](O)[C@@H]1O ATMYEINZLWEOQU-MOOMFTQBSA-N 0.000 description 1
- CEGXZKXILQSJHO-KODRXGBYSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC(F)=O CEGXZKXILQSJHO-KODRXGBYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- FPCWRPBDOPARID-UHFFFAOYSA-N 2,3,4-triphenyl-1H-tetrazol-4-ium dichloride Chemical compound [Cl-].[Cl-].C1(=CC=CC=C1)N1N(N([NH+]=C1)C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)N1N(N([NH+]=C1)C1=CC=CC=C1)C1=CC=CC=C1 FPCWRPBDOPARID-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 101100381518 Rattus norvegicus Bcl2 gene Proteins 0.000 description 1
- 101100497630 Rattus norvegicus Cxcr4 gene Proteins 0.000 description 1
- 101000713578 Rattus norvegicus Tubulin beta-3 chain Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
血清 | GFAP | MAP-2 | O4 | Tuj-1 |
2%hUCS | 15.2±3.1% | 12.1±3.1% | 9.4±2.1% | 10.2±1.7% |
10%FCS | 8.6±2.2% | 7.1±2.7% | 5.8±1.6% | 6.1±1.5% |
Claims (19)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510436042.4A CN106701668B (zh) | 2015-07-22 | 2015-07-22 | 间质干细胞、其纯株化扩张的方法及其应用 |
PCT/CN2015/094825 WO2017012226A1 (zh) | 2015-07-22 | 2015-11-17 | 间质干细胞、其克隆源性扩增的方法、其分离方法及其应用 |
EP15898782.6A EP3321356B1 (en) | 2015-07-22 | 2015-11-17 | Mesenchymal stem cell, method for culturing thereof, method for isolating thereof, and uses thereof |
ES15898782T ES2900819T3 (es) | 2015-07-22 | 2015-11-17 | Célula madre mesenquimal, método de cultivo de la misma, método de aislamiento de la misma y usos de la misma |
JP2017567682A JP6766082B2 (ja) | 2015-07-22 | 2015-11-17 | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510436042.4A CN106701668B (zh) | 2015-07-22 | 2015-07-22 | 间质干细胞、其纯株化扩张的方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106701668A true CN106701668A (zh) | 2017-05-24 |
CN106701668B CN106701668B (zh) | 2020-12-29 |
Family
ID=57833810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510436042.4A Active CN106701668B (zh) | 2015-07-22 | 2015-07-22 | 间质干细胞、其纯株化扩张的方法及其应用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3321356B1 (zh) |
JP (1) | JP6766082B2 (zh) |
CN (1) | CN106701668B (zh) |
ES (1) | ES2900819T3 (zh) |
WO (1) | WO2017012226A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107748260A (zh) * | 2017-08-29 | 2018-03-02 | 西安组织工程与再生医学研究所 | 一种脐带间充质干细胞促进组织工程预血管化的实验方法 |
CN111150743A (zh) * | 2018-11-06 | 2020-05-15 | 中国医药大学 | 间质干细胞在治疗多发性硬化症的用途 |
CN117018295A (zh) * | 2023-08-25 | 2023-11-10 | 苏州邦伊医疗科技有限公司 | 一种成活率高的自体脂肪移植方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108642004A (zh) * | 2018-05-17 | 2018-10-12 | 广东芙金干细胞再生医学有限公司 | 一种外泌体的制备方法及含有外泌体的干细胞增殖试剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085564A2 (en) * | 2006-09-20 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and methods involving truncated recombinant seven g-protein coupled receptors |
CA2669304C (en) * | 2006-11-30 | 2016-10-25 | Medipost Co., Ltd. | Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells |
KR20080049562A (ko) * | 2006-11-30 | 2008-06-04 | 가톨릭대학교 산학협력단 | 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제 |
JP5401669B2 (ja) * | 2007-12-06 | 2014-01-29 | 公益財団法人ヒューマンサイエンス振興財団 | 心筋細胞分化誘導促進方法及び分化誘導方法 |
CN101215545A (zh) * | 2007-12-31 | 2008-07-09 | 浙江大学 | 利用骨髓间充质干细胞诱导获得神经前体细胞的方法 |
CN101642469B (zh) * | 2009-09-09 | 2012-05-23 | 中国人民解放军海军总医院 | 脐带华通胶来源的间充质干细胞在急性心肌梗死细胞移植治疗中的应用 |
CN101690731B (zh) * | 2009-09-09 | 2013-07-10 | 中国人民解放军海军总医院 | 脐带华通胶源间充质干细胞在制备心力衰竭细胞移植材料中的应用 |
CN103060264B (zh) * | 2012-12-20 | 2015-01-21 | 上海市第十人民医院 | 一种干细胞培养基及其应用和干细胞培养方法 |
-
2015
- 2015-07-22 CN CN201510436042.4A patent/CN106701668B/zh active Active
- 2015-11-17 EP EP15898782.6A patent/EP3321356B1/en active Active
- 2015-11-17 ES ES15898782T patent/ES2900819T3/es active Active
- 2015-11-17 WO PCT/CN2015/094825 patent/WO2017012226A1/zh unknown
- 2015-11-17 JP JP2017567682A patent/JP6766082B2/ja active Active
Non-Patent Citations (5)
Title |
---|
AMER YOUSSEF等: "Low-Oxygen Tension and IGF-I Promote Proliferation and Multipotency of Placental Mesenchymal Stem Cells (PMSCs) from Different Gestations via Distinct Signaling Pathways", 《ENDOCRINOLOGY》 * |
MARK L.WEISS等: "Human Umbilical Cord Matrix Stem Cells: Preliminary Characterization And Effect Of Transplantation In A Rodent Model Of Parkinson’s Disease", 《STEM CELLS》 * |
SHIH-PING LIU等: "Nonsenescent Hsp27-Upregulated MSCs Implantation Promotes Neuroplasticity in Stroke Model", 《CELL TRANSPLANTATION》 * |
SUPHAKDE JULAVIJITPHONG等: "A Xeno-Free Culture Method That Enhances Wharton’s Jelly Mesenchymal Stromal Cell Culture Efficiency Over Traditional Animal Serume Supplemented Cultures", 《INTERNATIONAL SOCIETY FOR CELLULAR THERAPY》 * |
武丽萍等: "不同月龄人脐带间充质干细胞移植梗死心肌的血运重建", 《中国组织工程研究》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107748260A (zh) * | 2017-08-29 | 2018-03-02 | 西安组织工程与再生医学研究所 | 一种脐带间充质干细胞促进组织工程预血管化的实验方法 |
CN107748260B (zh) * | 2017-08-29 | 2020-05-15 | 西安组织工程与再生医学研究所 | 一种脐带间充质干细胞促进组织工程预血管化的实验方法 |
CN111150743A (zh) * | 2018-11-06 | 2020-05-15 | 中国医药大学 | 间质干细胞在治疗多发性硬化症的用途 |
CN117018295A (zh) * | 2023-08-25 | 2023-11-10 | 苏州邦伊医疗科技有限公司 | 一种成活率高的自体脂肪移植方法 |
CN117018295B (zh) * | 2023-08-25 | 2024-06-07 | 苏州邦伊医疗科技有限公司 | 一种成活率高的自体脂肪移植方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3321356A1 (en) | 2018-05-16 |
JP2018530992A (ja) | 2018-10-25 |
CN106701668B (zh) | 2020-12-29 |
ES2900819T3 (es) | 2022-03-18 |
WO2017012226A1 (zh) | 2017-01-26 |
JP6766082B2 (ja) | 2020-10-07 |
EP3321356B1 (en) | 2021-11-10 |
EP3321356A4 (en) | 2019-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101748096B (zh) | 亚全能干细胞、其制备方法及其用途 | |
US20230056048A1 (en) | Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell and method for obtaining multipotent umbilical cord mesenchymal stem cell | |
JP2005512592A5 (zh) | ||
AU2005293138A1 (en) | Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells | |
CN106701668A (zh) | 间质干细胞、其纯株化扩张的方法、其分离方法及其应用 | |
CN108368484A (zh) | 使用了血液细胞的组织、内脏器官的制作方法 | |
Lee et al. | Role of IGF1R+ MSCs in modulating neuroplasticity via CXCR4 cross-interaction | |
JP2018530992A6 (ja) | 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途 | |
CN109890398A (zh) | 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法 | |
CN103237887A (zh) | 胚胎干细胞来源的心肌细胞以及包含所述心肌细胞作为活性成分的细胞治疗剂 | |
CN102703380B (zh) | 亚全能干细胞、其制备方法及其用途 | |
CN102449139B (zh) | 对多能性干细胞和心肌细胞以外的分化细胞诱导细胞死亡的方法 | |
Yim et al. | Correlation between the immature characteristics of umbilical cord blood–derived mesenchymal stem cells and engraftment of hematopoietic stem cells in NOD/SCID mice | |
Lombaert et al. | Stem cells in salivary gland development and regeneration | |
CN106676056A (zh) | 诱导脐带间充质干细胞向胰岛素分泌样细胞分化的方法 | |
CN102822331A (zh) | 提高人干细胞活性的方法 | |
CN109652361A (zh) | 一种人脐静脉血管内皮细胞的原代分离培养及鉴定方法 | |
CN106676057A (zh) | 诱导脐带间充质干细胞向胰岛素分泌样细胞分化的无血清培养基及其制备方法和用途 | |
CN102533641B (zh) | 体外无血清成体干细胞放大培养的方法及其培养液 | |
CN110484496A (zh) | 一种天然小分子化合物诱导脐带间充质干细胞成骨分化的用途 | |
KR20080094431A (ko) | 말초 혈액 유래 단핵 세포로부터 신경 전구 세포를 분리,배양 및 분화하는 방법 | |
US11110129B2 (en) | Method for treating multiple sclerosis | |
WO2023286834A1 (ja) | 血管内皮増殖因子(vegf)高発現ペリサイト様細胞 | |
WO2023286832A1 (ja) | 血管内皮増殖因子(vegf)高発現ペリサイト様細胞の製造方法 | |
CN106497870A (zh) | 一种组合物、含有该组合物的诱导制剂及诱导方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240423 Address after: West Key Avenue, Rockville, Maryland, United States Patentee after: Qilong Cell Biotechnology Co.,Ltd. in the United States Country or region after: U.S.A. Address before: China Taiwan Road No. 91 in Taichung City Patentee before: CHINA MEDICAL University Country or region before: TaiWan, China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240515 Address after: 9400 West Key Avenue, Rockville, Maryland, USA, Room 200-202 Patentee after: Qilong Pharmaceutical Co.,Ltd. in the United States Country or region after: U.S.A. Address before: West Key Avenue, Rockville, Maryland, United States Patentee before: Qilong Cell Biotechnology Co.,Ltd. in the United States Country or region before: U.S.A. |